tiprankstipranks
Actinogen Medical Touts Cognitive Therapy Breakthrough
Company Announcements

Actinogen Medical Touts Cognitive Therapy Breakthrough

Actinogen Medical Limited (AU:ACW) has released an update.

Actinogen Medical Limited is hosting a ‘plain English’ science forum today to discuss their lead compound, Xanamem, which shows promise in treating cognitive impairment in various diseases, including Alzheimer’s and Depression. The event features a panel with Actinogen’s CMO and guest professors, providing an opportunity for questions and will be accessible later via the company’s online channels. Xanamem operates by targeting brain cortisol levels, which have been linked to cognitive decline, and has shown potential in early clinical trials.

For further insights into AU:ACW stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskActinogen Medical’s Promising Clinical Trials Progress
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Seeks Quotation for New Shares
TipRanks Australian Auto-Generated NewsdeskActinogen Medical Seeks New Securities Quotation
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!